This major conference brings together over 3,000 academics, scientists, and representatives from the pharmaceutical industry to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology. During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development and the execution of large, prospective, randomized, multicenter cancer clinical trials. Together, the level of excitement surrounding targeted therapy and the high caliber of the science presented fuel the power of this meeting to attract the world’s leaders in the development of new cancer therapeutics.